Stockwinners Market Radar for June 22, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:32 EDT Marvell CEO sells $1.83M in common stock - In a regulatory filing, Marvell disclosed that its CEO sold 30K shares of common stock on June 20th in a total transaction size of $1.83M.

20:03 EDT Cathie Wood's ARK Investment bought 113.5K shares of Verve Therapeutics today

19:51 EDT Stifel Financial reports May total client assets of $402.4B vs. $406.6B in April - Ronald J. Kruszewski, CEO, said, "In May, total deposits increased while client cash balances were relatively flat with April's levels. Through the first two months of the quarter, we experienced consistent growth in Smart Rate balances and have seen cash sorting continue to slow during June. Total client assets declined as solid recruiting was offset by declines in equity markets. Operating conditions for investment banking and our transactional businesses remain challenging. As such, we estimate that second quarter investment banking and transactional revenue will be down 10-15% and 5-10%, respectively, from the prior quarter."

19:32 EDT Celanese, Mitsui to form food ingredients joint venture - Celanese (CE) and Mitsui (MITSY) "announced the signing of a definitive agreement to form a Food Ingredients joint venture under the name Nutrinova. Celanese will contribute the assets, technology and employees of its Food Ingredients business while retaining a 30% stake in the joint venture. Mitsui will acquire the remaining 70% stake at a purchase price of $472.5M, representing an enterprise valuation of approximately 15 times 2022 EBITDA. The parties expect to close the transaction in the second half of 2023, pending regulatory approvals. The Nutrinova joint venture builds upon the existing long-term strategic partnership between the two companies. The agreement combines the technology, product portfolio and backward integration of the Celanese Food Ingredients business with Mitsui's long-standing positions across the food value chain in Asia and other regions. Additionally, Celanese will continue to meet the full acetyls raw material needs of the Nutrinova JV under a long-term supply agreement. The formation of the Nutrinova JV allows Celanese to monetize a majority of that business in a value accretive way and also maintain the benefits of integration with the Acetyl Chain. After consideration of closing expenses and transaction costs, an estimated net cash proceeds of approximately $450 million will be fully utilized to pay down debt, which is a meaningful step in the company's deleveraging plan."

19:11 EDT UiPath director Wong sells 43,451 class A shares - In a regulatory filing, UiPath director Rich Wong disclosed the sale of 43,451 class A common shares of the company on June 20 at a price of $17.9808 per share.

18:36 EDT HireRight board authorizes additional $25M share repurchase program - HireRight Holdings Corporation announced its Board of Directors has authorized an additional $25M share repurchase program. Under the repurchase program, the Company may purchase shares of its common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions, or other means, including through Rule 10b5-1 trading plans. The timing and actual number of shares repurchased will depend on a variety of factors, including stock price, trading volume, market conditions and other general business considerations. The repurchase program may be modified, suspended, or terminated at any time.

18:15 EDT Intercept trading resumes

17:49 EDT Intercept's New Drug Application for obeticholic acid in NASH rejected by FDA - Intercept announced that the FDA has issued a Complete Response Letter in response to the company's New Drug Application - NDA - for obeticholic acid for the treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis, or NASH. The FDA indicated in the CRL that it has completed its review of the NDA and determined that it cannot be approved in its present form. Based on the content of the CRL, any resubmission of an NDA for OCA in NASH would require, at a minimum, successful completion of the long-term outcomes phase of the REGENERATE study. As a result of the CRL, Intercept has decided to discontinue all NASH-related investment, restructure the company's operations to strengthen its focus on rare and serious liver diseases, and drive an accelerated path to profitability beginning in 2024.

17:40 EDT Intercept trading halted, news pending

16:47 EDT Owl Rock changing name and ticker to Blue Owl Capital Corporation - Owl Rock (ORCC) will soon be changing its name, ticker, and website. The company's board of directors has already approved these changes and no shareholder vote is required. Effective July 6, the company is taking the following actions: changing its name to "Blue Owl Capital Corporation"; updating its ticker symbol with the New York Stock Exchange from "ORCC" to "OBDC"; and changing its website to www.blueowlcapitalcorporation.com. Owl Rock Capital is managed by an investment adviser that is an indirect affiliate of Blue Owl Capital (OWL) and this name change will not change the day-to-day business of the company, but rather is part of a broader initiative to have one Blue Owl brand. In addition, the company's adviser, Owl Rock Capital Advisors intends to change its name to "Blue Owl Credit Advisors", effective July 6. CUSIPs for the equity and unsecured notes of the company will not change. Additionally, existing CLOs issued by special purpose vehicles of the company will not be renamed.

16:45 EDT Skillz announces 1-for-20 reverse stock split - Skillz announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's Class A common stock and Class B common stock. The reverse stock split, which was authorized by Skillz stockholders at the Annual Meeting of Stockholders on June 20, 2023, is intended to return Skillz to compliance with the New York Stock Exchange continued listing standards. The reverse stock split will become effective on June 23, 2023 and the Company's Class A common stock will begin trading on a split-adjusted basis when the market opens on June 26, 2023. Skillz' Class A common stock will continue to trade on the New York Stock Exchange under the ticker symbol "SKLZ" but with a new CUSIP number of 83067L208.

16:41 EDT Brunswick provides operational update after IT incident - Brunswick reported an IT security incident on June 13 that impacted some of its systems and global facilities. The company activated its response protocols, which included pausing operations in some locations, and engaging leading security experts and law enforcement to assist. Since that time, Brunswick has made "significant" progress restoring the functionality of its systems and restarting operations at facilities where production or distribution was paused. All primary Brunswick global manufacturing and most distribution facilities are now operational, with the remaining production and distribution facilities expected to restart within a few business days. Given the proximity of the production and distribution disruptions to the end of Q2, the process of catching up lost production and fulfilling backorders will continue through at least Q3.

16:37 EDT Trupanion jumps 17% to $24.06 after rate increase update for NY and CA

16:33 EDT Rocket Lab to launch multiple satellites as part of upcoming recovery mission - Rocket Lab USA "announced its next Electron mission will deploy seven satellites to space and include an attempt to recover the rocket's booster after launch. The 'Baby Come Back' mission, Rocket Lab's 39th Electron launch, is scheduled to deploy from Pad A at Rocket Lab Launch Complex 1 in Mahia, New Zealand during a launch window that opens July 14, 2023 UTC. Rocket Lab is also planning to conduct a marine recovery of Electron's first stage as part of this mission. Rocket Lab's recovery team will retrieve Electron using a customized vessel and transport the stage back to Rocket Lab's production complex for analysis. Data from this recovered stage will inform Rocket Lab's ongoing recovery and reuse program."

16:23 EDT Biodexa Pharma announces ADR ratio change to one ADR represents 400 shares - Biodexa Pharmaceuticals announces a ratio change on its American Depositary Receipts from one ADR representing five ordinary shares, to the new ratio of one ADR representing four hundred ordinary shares . The effective date of the Ratio Change is expected to be 5 July.

16:21 EDT Sterling Bancorp says SEC concludes investigation into company - Sterling Bancorp announced it received a letter from the Division of Enforcement of the U.S. Securities and Exchange Commission informing the company that the Division of Enforcement had concluded its investigation of the company and does not intend to recommend an enforcement action by the SEC against the company. As previously disclosed, the company understands that the SEC investigation related to accounting, financial reporting and disclosure matters, as well as the company's internal controls, related to the company's now-terminated Advantage Loan Program.

16:17 EDT Sonic Automotive suspends operations at eight EchoPark locations - Sonic Automotive announced the implementation of its plans to align the EchoPark brand with current pre-owned market conditions that are being negatively impacted by lower production of new vehicles over the past three years and historically low lease penetration and lease returns, resulting in lower availability of used vehicles and higher wholesale prices with unpredictable volatility. In accordance with this plan, Sonic has indefinitely suspended operations at eight EchoPark locations and additional related Delivery/Buy Centers which will enable Sonic to allocate more vehicles to key markets and increase capacity to address current demand in those markets. The enhancement of inventory mix at the remaining EchoPark stores, coupled with expense reductions from this action, are expected to improve EchoPark's short-term financial performance while maintaining the foundation for the brand's national expansion and its continuation of providing the best guest experience in automotive retail. Sonic has positioned EchoPark to quickly adjust as market conditions change. Recent data shows improvement in pre-owned wholesale pricing but Sonic expects continued volatility in the wholesale price environment into 2024. Improvements in wholesale pricing will benefit consumer affordability as well as the overall profitability of the EchoPark model. Additionally, expected new vehicle production increases over the next 12-18 months will benefit pre-owned availability and further improve both consumer affordability and EchoPark profitability. These improvements in market conditions will enable Sonic to continue the expansion of EchoPark's geographic footprint into new markets. Sonic maintains the goal of EBITDA breakeven for the EchoPark segment by the first quarter of 2024. Sonic also maintains the goal of reaching 90% of the U.S. population with EchoPark, which was previously communicated to be achieved by 2025. Sonic now believes that the timing of achieving this goal will be predicated on how quickly the pre-owned market normalizes related to inventory availability and pricing. Currently, Sonic's focus is on improving EchoPark's financial performance. In conjunction with these plans, Sonic expects to record a one-time charge in the second quarter of 2023, ranging between $60 million to $80 million, all of which is non-cash except $3 million to $5 million.

16:16 EDT Absolute Software says ISS, Glass Lewis urge investors vote for Crosspoint deal - Absolute Software announced that both leading independent proxy advisors, Institutional Shareholder Services Inc. and Glass Lewis & Co., have recommended Absolute shareholders vote FOR the plan of arrangement with Crosspoint Capital Partners, L.P. Absolute shareholders will receive an all-cash consideration of US$11.50 per share under the terms of the Arrangement, which represents a premium of approximately 34% to the closing price of Absolute common shares on the Nasdaq Global Market on May 10, 2023, and a premium of approximately 38% to the Company's 30-day volume-weighted average price of the Shares on the NASDAQ for the period ending on May 10, 2023, being the last trading day on the NASDAQ prior to the execution of the Arrangement Agreement.

16:15 EDT Shapeways 1-for-8 reverse stock split becomes effective - Shapeways Holdings announced that its previously announced 1-for-8 reverse stock split of the Company's common stock, par value $0.0001 per share, and corresponding common stock adjustment became effective at 4:01 p.m. Eastern Time on June 22, 2023. The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange when the markets open on June 23, 2023, under the existing trading symbol "SHPW" and new CUSIP number: 81947T201. The primary goal of the reverse stock split is to increase the per share market price of the Company's common stock to meet the minimum $1.00 average closing price requirement for continued listing on the NYSE. As a result of the reverse stock split, every eight shares of the Company's issued and outstanding common stock automatically combined into one share of issued and outstanding common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, each stockholder will be entitled to receive a cash payment in lieu thereof at a price equal to the fraction of one share to which the stockholder would otherwise be entitled multiplied by the closing price per share of the Company's common stock on the NYSE on June 22, 2023. The reverse stock split did not reduce the number of authorized shares of the Company's common stock or change the par value of the common stock. The reverse stock split affects all stockholders uniformly and does not affect any stockholder's ownership percentage of the common stock (except to the extent that the reverse stock split would result in any stockholders owning a fractional share). In addition, the terms of all outstanding options, warrants, and restricted stock units are being proportionately adjusted, in accordance with the terms of the applicable agreement.

16:14 EDT Compass Therapeutics to be added to Russell 2000, 3000 Indexes June 26 - Compass Therapeutics announced that it will be added to the Russell 2000 and Russell 3000. Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26. "We are pleased to be added to the Russell Indexes," said Vered Bisker-Leib, President & COO of Compass Therapeutics. "The inclusion of Compass will enhance trading activity of our stock and broaden our exposure to the investment community, which may help accelerate our efforts to develop next generation antibodies into transformative cancer therapies that improve patients' lives."

16:11 EDT LinkBancorp, Partners Bancorp shareholders approve merger - LinkBancorp ( LNKB) and Partners Bancorp (PTRS) announced that at special meetings of their respective shareholders held on June 22, Link and Partners shareholders approved the merger of Partners with and into Link, with Link as the surviving corporation. The closing of the proposed merger remains subject to regulatory approvals and certain other customary closing conditions.

16:09 EDT Four Corners Property Trust acquires three Mo'Bettahs Properties for $6.6M - Four Corners Property announces the acquisition of three Mo'Bettahs properties for $6.6M. Established in 2008, Mo'Bettahs is a Hawaiian-style quick service restaurant backed by Savory Brands. The properties are newly constructed and located in strong retail corridors in Kansas, Missouri, and Oklahoma and are occupied under a long-term, triple net lease with approximately 15 years of term remaining. The transaction was priced at a cap rate in range with previous FCPT transactions.

16:08 EDT FDA grants Erasca ODD for ERAS-801 to treat malignant glioma, including GBM - Erasca announced the United States Food and Drug Administration FDA has granted Orphan Drug Designation ODD to ERAS-801 for the treatment of malignant glioma, which includes glioblastoma, GBM. ERAS-801 is an orally bioavailable, small molecule EGFR inhibitor that exhibited substantial central nervous system penetration in preclinical animal studies. "Receiving ODD recognizes both the importance of innovation for patients with GBM and the therapeutic potential of ERAS-801 to provide a targeted treatment option for these patients, who have a poor prognosis. This ODD follows the earlier Fast Track Designation granted to ERAS-801 by the FDA and underscores the urgency of finding new treatments for this patient population. The broad activity against both oncogenic and wildtype EGFR, high CNS penetration, and demonstrated ability to improve outcomes in over 90% of diverse EGFR-driven patient-derived glioma models support the potential for ERAS-801 to overcome current challenges with existing therapies. We anticipate reporting initial monotherapy data for ERAS-801 from the Phase 1 THUNDERBBOLT-1 trial in patients with recurrent GBM in the second half of 2023." ERAS-801 was designed and developed by a renowned team of cancer researchers-Michael Jung, Ph.D., Timothy Cloughesy, M.D., and David Nathanson, Ph.D.

16:07 EDT SAIC awarded $1.3B contract from U.S. Treasury Department - Science Applications International Corp. has been awarded a $1.3B single source seven-year contract by the Department of the Treasury to provide T-Cloud, a complete range of cloud and professional services. "T-Cloud will enable the Treasury Department to rapidly and securely adopt a modern, flexible and cost-effective approach to utilizing and consuming data in the cloud," said Bob Genter, President, Defense and Civilian Sector at SAIC. "SAIC is honored to be the Treasury Department's cloud services digital transformation partner." The T-Cloud contract supports Treasury's adoption and transformation of a multi-cloud environment by centralizing management of the systems infrastructure, platform and software-as-a-service by a single broker. In addition to full suites of AWS, Microsoft, Google, IBM and Oracle cloud services, there is additional opportunity to onboard new cloud service providers.

16:06 EDT Performant Financial set to join Russell 3000 Index - Performant Financial Corporation announced that the company is set to join the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28, ranking them by total market capitalization, including both the Russell 3000 and Russell Microcap Indexes. Membership in the US all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

15:43 EDT ETAO International receives noncompliance letter from Nasdaq - Etao International received a bid price deficiency letter from Nasdaq notifying the company that listed securities to maintain a minimum bid price of $1 per share. Based upon the closing bid price for the last 30 consecutive business days, the company no longer meets this requirement. However, the rules also provide the company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the company's security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the company written confirmation of compliance and this matter will be closed. Please note that if the company chooses to implement a reverse stock split, it must complete the split no later than ten business days prior to the expiration date of December 11 in order to regain compliance.

15:32 EDT Alpha Pro Tech board authorizes $2M expansion of share repurchase program - Alpha Pro Tech announced that its Board of Directors has authorized a $2M expansion of the company's existing share repurchase program. With this authorized expansion, the company now has approximately $2.3M available to repurchase shares of the company's common stock, $0.3M of which remains from the previous expansion, most recently announced in December 2022.

14:39 EDT C3.ai CFO says sales cycles shortening, deal activity accelerating - C3.ai CFO Juho Parkkinen said during the company's investor day event, according to a transcript: "So with with this broad interest in AI, let's see what it's doing to basically the metrics that we look at on a day in, day out and weekly basis. And so first is the pipeline. And the pipeline is basically doubled and qualified opportunities from the prior year. So we went from roughly just under 300 qualified opportunities to over 600 qualified opportunities at the beginning of this fiscal year. Sales cycles are shortening. So six, seven years ago they were over a year and discussion about the cloud, about Iot, about AI, etc. and now everybody is basically on board and want to deploy very quickly. So we're down to under four months, average sales cycles here, pilots, so significant interest in engaging in pilots and doing them. And so this is quarter to date. So roughly halfway through this quarter as compared to halfway through last quarter, you'll see this triple the number of pilots that we've actually closed relative to last quarter, number of deals have also accelerated. So as the comparison to again midway through the quarter a year ago for first quarter and now we're basically seeing 60% increase in the number of deals that we've heard today. Yeah, this is yeah, it's quarter to date. So at this point in the quarter, roughly halfway through a year ago, we did ten deals and this year this quarter excuse me, we've done 16 to date."

14:21 EDT Sarepta down 1% after resuming trading - Shares of Sarepta are down $1.49, or 1%, to $125.38 after resuming trading following the company's announcement that the FDA granted accelerated approval of Elevidys gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy, or DMD, with a confirmed mutation in the DMD gene.

14:14 EDT C3.ai down 5% as company conducts investor day - C3.ai shares are down over 5% to $36.90 in afternoon trading as the company conducts its investor day meeting, which began at 1:30 pm ET. Reference Link

14:08 EDT Gray renews CBS network affiliations covering all 54 existing markets - Gray Television (GTN) has entered into a new agreement with Paramount Global (PARA) that renews all of Gray's existing CBS network affiliations, encompassing seven markets acquired from Meredith Corporation and 47 legacy markets. As part of the agreement, Gray's CBS affiliates will continue to be available locally to subscribers on Paramount+ and widely distributed across all traditional and virtual MVPD platforms. Gray is the largest independent owner of CBS affiliates in the country, covering nearly 18% of the U.S. television households and nearly 22 million households, the company noted. "At a time when local news is more valued than ever - and under greater pressure than ever - Gray is very pleased to have reached an agreement that builds upon the decades-long relationship with CBS in dozens of markets, large and small. With this renewal, we intend to continue to invest in local news, weather and sports reporting, while bringing CBS' premium programming to our local communities," said Pat LaPlatney, Co-CEO of Gray Television.

14:01 EDT CPKC, CSX to collaborate to develop additional hydrogen locomotives - Canadian Pacific Kansas City (CP) and CSX Corporation (CSX) announced their intent to enter into a joint venture for the building and deployment of hydrogen locomotive conversion kits for diesel electric locomotives. As an initial step in the collaboration, CSX plans to convert one of its diesel locomotives using a hydrogen conversion kit developed by CPKC. The conversion work will be done at CSX's Huntington, West Virginia locomotive shop. "This innovative collaboration expands our hydrogen locomotive program beyond a single railroad and represents an exciting next step in proving the long-term viability of hydrogen as a solution to emissions reduction for our industry. Our hydrogen locomotive went from concept to reality in 24 months with the first zero emissions hydrogen locomotive having already pulled freight in revenue service. We look forward to this collaboration as we work to create a lower carbon future," said Keith Creel, CPKC president and CEO.

13:33 EDT Sarepta trading halted, news pending

13:29 EDT Siemens Energy withdraws profit guidance due to Siemens Gamesa - Siemens Energy (SMNEY) is withdrawing its profit guidance due to Siemens Gamesa (GCTAF). The company said: "Following the substantial increase in failure rates of wind turbine components, the board of Siemens Gamesa initiated an extended technical review of Siemens Gamesa's installed fleet and product designs. The current status of the technical review suggests that in order to reach the targeted product quality of certain Onshore platforms, significantly higher costs will be incurred than previously assumed. Potential quality related measures and the associated costs are currently under evaluation and are likely to be in excess of EUR 1B. We are also reviewing assumptions critical to the existing business plans given productivity improvements are not materializing to the extent previously expected. In addition, we continue to experience ramp up challenges in Offshore. It is too early to have an exact estimate of the potential financial impact of the quality topics and to gauge the impact of the review of our assumptions on our business plans. However, based on our initial assessment as of today, the potential magnitude of the impact leads us to withdraw the profit assumptions for Siemens Gamesa and consequently the profit guidance for Siemens Energy Group for fiscal year 2023. We maintain our revenue guidance for the Group as well as all our assumptions for Gas Services, Grid Technologies and Transformation of Industry."

13:05 EDT General Motors names Lin-Hua Wu as Chief Communications Officer - General Motors (GM) named Lin-Hua Wu as senior vice president and Chief Communications Officer. Wu joins GM from Google (GOOGL), where she was Vice President of Global Communications & Public Affairs since 2021. Wu's appointment is effective Aug. 21. She will report to GM Chair and CEO Mary Barra.

12:44 EDT FactSet says 'too early' to talk about 2024 - FactSet, on its Q3 earnings conference call, said that it is "too early to talk about 2024," but takes "very seriously" the responsibility of right-sizing the cost base so the company can hit its margin and EPS targets.

12:18 EDT SmartMetric announces adoption of biometric credit cards by Visa, MasterCard - SmartMetric (SMME) announced that Visa (V) and MasterCard (MA) have adopted the use of biometric credit cards over their respective payment networks. "SmartMetric is the original developer of biometric credit cards and having spent literally years and millions of dollars in R&D to reduce the size of biometric electronics to fit inside a credit card, finds that it has created the most advanced and user-friendly biometric credit card in the world," said SmartMetric's President and CEO, Chaya Hendrick.

12:02 EDT ITT announces EUR50M investment for expansion into brake pad applications - ITT Inc. announced an expansion of its Friction production facility in Termoli, Italy and an upgrade of its research and development capabilities in Barge, Italy to establish a position in the high-performance brake pads market for luxury and sporting vehicles. Friction, a part of ITT's Motion Technologies segment, is a global brake pad supplier for the automotive market. The initial EUR 50M investment increases the Termoli plant's covered surface by 75% and includes fast prototyping, expanded testing machinery and an automated production module designed to handle the demanding specifications of high-performance brake pads, ITT said in a statement, adding that as part of the investment, ITT will install solar panels that will provide approximately 20% of the Termoli site's electricity needs.

12:00 EDT Spirit AeroSystems falls -9.3% - Spirit AeroSystems is down -9.3%, or -$2.76 to $26.92.

12:00 EDT Despegar.com rises 7.6% - Despegar.com is up 7.6%, or 53c to $7.51.

12:00 EDT Steelcase rises 10.6% - Steelcase is up 10.6%, or 77c to $8.01.

11:15 EDT Muscle Maker's Sadot enters agreement with Buenaventura Trading - Muscle Maker announced that its subsidiary, Sadot, has expanded its agri-commodity sourcing and trading operations into North, Central and South America, further diversifying the company's geographic reach beyond its existing operations in Europe, Asia, the Middle East and Africa. The expansion was facilitated by a strategic agreement between Sadot's agri-food operations and newly-formed Buenaventura Trading based in Miami FL. Buenaventura's team brings exposure to new trade routes throughout the Americas by adding multiple sourcing and trading consultants to Sadot with backgrounds from several of the largest international food supply chain organizations. In order to support the expansion into the Americas and our agreement with Buenaventura, Sadot has formed a new subsidiary, Sadot Latam.

11:13 EDT MongoDB launches four capabilities for developers to reduce operational overhead - MongoDB at its developer conference MongoDB.local NYC announced new capabilities for the NoSQL database for building modern applications faster and with less heavy lifting. The company said, "The new tools empower developers to do their best work-including additional programming language support for using infrastructure-as-code to deploy MongoDB Atlas on AWS and building server-side applications with Kotlin, streamlined capabilities for MongoDB Atlas Kubernetes Operator, and the general availability of the the PyMongoArrow library for more efficient data analysis using Python. Together, these new capabilities expand MongoDB's mission to meet developers where they are by integrating the tools they love in a single developer data platform to make it faster and easier to build applications."

11:08 EDT MongoDB announces general availability of MongoDB Relational Migrator - MongoDB at its developer conference MongoDB.local NYC announced the general availability of MongoDB Relational Migrator, a new tool it said, "simplifies application migration and transformation-from legacy relational to modern document-based data models-providing organizations a streamlined way to improve operational efficiency and get more out of their data." Already in use by tens of thousands of customers and millions of developers around the world, MongoDB Atlas's document model and scale-out capabilities are helping customers build modern applications that leverage the latest technologies, empowering them to reimagine business operations and end-user experiences. The company said, "Now, with MongoDB Relational Migrator, more organizations across all industries can quickly, easily, cost-effectively, and with little-to-no risk migrate from legacy databases and embrace the future."

11:06 EDT MongoDB announces launch of Atlas for Industries - MongoDB, at its developer conference, MongoDB.local NYC, announced MongoDB Atlas for Industries, which it calls a new program to "help organizations accelerate cloud adoption and modernization by leveraging industry-specific expertise, programs, partnerships, and integrated solutions." The company stated: "With MongoDB Atlas for Industries, customers have access to expert-led architectural design reviews, technology partnerships that deliver enhanced solutions for industry-specific challenges, and industry-specific knowledge accelerators to provide highly relevant technology training paths for development teams. MongoDB Atlas for Industries is launching its first set of vertical solutions for financial services, an industry that is changing rapidly with shifts in automation and technology advancements. With MongoDB Atlas, financial institutions can improve customer experiences by modernizing legacy functionality on existing in-house banking systems and building composable architectures-architectures that make it easy to integrate industry-leading software tools-to get ideas to market faster with the performance and scale they need. MongoDB Atlas for Industries programs for manufacturing and automotive, insurance, healthcare, retail and other industries will follow over the course of the year."

11:03 EDT MongoDB launches AI initiative with Google Cloud - MongoDB (MDB) today at its developer conference MongoDB.local NYC announced a new initiative in partnership with Google Cloud (GOOGL) to help developers accelerate the use of generative AI and build new classes of applications. "MongoDB Atlas is the multi-cloud developer data platform used by tens of thousands of customers and millions of developers globally to quickly build and scale applications using a single platform. With an integrated operational data store at its core, MongoDB Atlas is uniquely positioned to help organizations of all shapes and sizes build applications powered by generative AI faster and with less complexity. Developers can now take advantage of MongoDB Atlas and industry-leading partner integrations with Google Cloud's Vertex AI large language models - LLMs - and new quick-start architecture reviews with MongoDB and Google Cloud professional services to accelerate software development," MongoDB stated.

10:25 EDT JPMorgan to pay $4M to settle SEC charges of deleting electronic records - JPMorgan has submitted an offer of settlement that the Securities and Exchange Commission has determined to accept related to proceedings that arise out of the deletion by JPMorgan of approximately 47 million electronic communications in about 8,700 electronic mailboxes relating to the period January 1 through April 23, 2018, many of which were business records required to be retained. JPMorgan shall pay a civil money penalty in the amount of $4M to the Securities and Exchange Commission for transfer to the general fund of the United States Treasury, the agency stated in a document posted to its website. Reference Link

10:16 EDT Alphia, Better Choice announce long-term strategic manufacturing partnership - Alphia announced a long term strategic manufacturing partnership with Better Choice Company, a pet health and wellness company. Along with a $5M investment made by Alphia into Better Choice, Alphia will become the manufacturer for its premier brand, Halo, a super-premium pet food brand found in pet specialty stores.

10:04 EDT Ford wins $9.2B DOE loan to build EV battery factories - The U.S. Department of Energy's Loan Programs Office announced a conditional commitment for a loan of up to $9.2B to BlueOval SK LLC for the construction of three manufacturing plants to produce batteries for Ford Motor Company's future Ford and Lincoln electric vehicles. Together, the plants, one located in Tennessee and two in Kentucky, will enable more than 120 gigawatt hours of U.S. battery production annually and displace more than 455 million gallons of gasoline per year for the lifetime of the vehicles powered by these batteries, the DOE said in a statement. The project is expected to create a total of approximately 5,000 constructions jobs in Tennessee and Kentucky, and 7,500 operations jobs once the plants are up and running. This effort supports President Biden's Investing in America agenda to onshore and re-shore domestic manufacturing of technologies that are critical to reaching the clean energy and transportation future, the DOE added. BOSK is a joint venture between Ford and SK On, a Korean EV battery manufacturer. Reference Link

10:00 EDT Gulfport Energy falls -8.5% - Gulfport Energy is down -8.5%, or -$9.14 to $98.74.

10:00 EDT Scor ADR rises 5.6% - Scor ADR is up 5.6%, or $1.38 to $26.16.

10:00 EDT Steelcase rises 8.7% - Steelcase is up 8.7%, or 63c to $7.87.

09:47 EDT Gulfport Energy falls -7.0% - Gulfport Energy is down -7.0%, or -$7.51 to $100.37.

09:47 EDT Spirit AeroSystems falls -10.2% - Spirit AeroSystems is down -10.2%, or -$3.03 to $26.65.

09:47 EDT Steelcase rises 7.0% - Steelcase is up 7.0%, or 51c to $7.75.

09:46 EDT Trxade Health Inc trading resumes

09:43 EDT Knightscope announces purchase order for two additional K1 Blue Light Towers - Knightscope announced that a University in New Jersey signed a purchase order for two additional K1 Blue Light Towers adding to the $1.25M order announced earlier this year. In addition, Transcend Security Solutions, one of Arizona's largest, premier contract security providers, extended its K5 Autonomous Security Robot contract at a popular Arizona shopping mall for the third year.

09:32 EDT Trxade Health Inc trading halted, volatility trading pause

09:31 EDT Rocket Lab signs dedicated launch deal with Spire Global - Rocket Lab (RKLB) announced that it has signed a dedicated launch deal with Spire Global (SPIR) to deliver its first four Space Situational Awareness, or SSA, satellites to low Earth orbit for its Space Services customer NorthStar Earth & Space Inc. The dedicated mission on Electron will deploy the satellites to a 530km circular orbit from Rocket Lab Launch Complex 1 in New Zealand during a launch window that opens in September. To meet NorthStar's program requirements, Spire has selected Rocket Lab to launch the satellites on an accelerated timeline within five months of contract signing. Spire has previously launched with Rocket Lab on Electron's first two commercial missions, Still Testing and Its Business Time, in 2018.

09:28 EDT Lexaria Bioscience announces publication on DehydraTECH-CBD research - Lexaria Bioscience announces that its research utilizing DehydraTECH-processed cannabidiol has now been published in eight peer-reviewed articles in six different publications. The most recent paper entitled, "Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study" was published in June, 2023 in the peer-reviewed International Journal of Molecular Sciences. "We're proud of the impressive amount of research that our Company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers," said John Docherty, President of Lexaria. "Lexaria is establishing itself as one of the world's leaders in the investigation of cannabidiol for the purposes of controlling human blood pressure and we are now focused on launching a FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year."

09:20 EDT Academy Sports promotes Matt McCabe to Chief Merchandising Officer - Academy Sports announced that Matt McCabe has been promoted to Executive VP and Chief Merchandising Officer effective June 25, succeeding Steve Lawrence, who recently transitioned to CEO. McCabe has served as Academy's Senior VP, General Merchandise Manager, Footwear since September 2017. He joined the company in December 2016 as Vice President, Divisional Merchandise Manager, Athletic and Licensed Apparel. Prior to joining Academy, he served as Vice President at Golfsmith International, where he led the apparel, footwear, and soft consumables buying and private brand businesses. He has also held various merchant leadership roles at The Bon Ton Department Stores, Bachrach, Sears & Roebuck Co., and Mark Shale.

09:19 EDT NRG Energy working with independent search firm to bring expertise to board - NRG announced that it is working with an independent search firm and evaluating feedback from NRG shareholders to bring additional expertise to the Board. "This is part of an ongoing, deliberate process to evolve board composition with a focus on diverse skills and experiences in alignment with the Company's strategy," NRG said.

09:19 EDT NRG Energy extends financial outlook through 2027 - NRG Energy will host a virtual Investor Day during which management will provide an update on its consumer services strategy, as well as the Company's new capital allocation framework and operating efficiency initiatives. "We are better positioned than ever before to capitalize on NRG's market leadership in energy and the relationships we have built with millions of customers," said Lawrence Coben, Chair of the NRG Board of Directors. "We fully support Mauricio and the management team and are confident in our strategy and ability to deliver superior, sustainable shareholder value." NRG expects free cash flow before growth per share to increase approximately 15% to 20% on a compounded annual basis between 2023 and 2027. This equates to $8.3 billion of cumulative excess cash after deleveraging - exceeding NRG's current market cap. NRG has updated its capital allocation framework and plans to, after deleveraging, return 80% of excess cash to shareholders and invest 20% in growth initiatives; this compares to the Company's prior 50% / 50% allocation. As a result of the expected cash flow generation, the Company expects $6.9 billion of cumulative capital returns to shareholders through share repurchases and dividends through 2027. The Company's Board of Directors has increased the share repurchase authorization from $1.0 billion to $2.7 billion through 2025. NRG expects 7% to 9% long-term annual dividend per share growth. In addition to significant capital returns to shareholders, NRG expects to complete up to $2.55 billion of debt reduction to enable NRG to achieve its target investment grade credit metrics of 2.5x to 2.75x net debt / adjusted corporate EBITDA by 2025, aligning with rating agency and counterparty expectations.

09:18 EDT Edible Garden announces grant funding from West Michigan Works!, MDARD - Edible Garden has received funding from West Michigan Works! and the Michigan Department of Agriculture and Rural Development Specialty Crop Block Program. These funds are designated to reimburse Western Michigan employers for expenses associated with leadership and food safety training. The Specialty Crop Block Grant Program, which enhances the competitiveness of Michigan's specialty crops such as fruits, vegetables, tree nuts, dried fruits, and horticulture, awards grants to organizations that demonstrate potential impacts and quantifiable results for the specialty crop industry and/or the public.

09:14 EDT Two Harbors reduces quarterly dividend to 45c per share - Two Harbors Investment last night declared a dividend of 45c per share of common stock for the second quarter of 2023. The second quarter dividend is payable on July 28 to common stockholders of record at the close of business on July 5. "The common stock dividend is a function of several factors, including sustainability, earnings and return potential of the portfolio, taxable income, impact to book value and the market environment," the company stated. "The decision to reduce the dividend this quarter was not a function of downward pressure on earnings, but rather a strategic focus on enhancing book value and further investing capital into a positive Agency MSR and MBS environment. We believe that at this level the dividend will be sustainable and competitive, while allowing us to invest additional capital at very attractive spreads and grow our MSR business," added Bill Greenberg, Two Harbors' President and CEO.

09:09 EDT EnWave, Bridgford Foods sign commercial license agreement - EnWave Corporation (NWVCF) has announced the signing of a royalty-bearing commercial license with Bridgford Foods Corporation (BRID) for the manufacture of certain military ration products using EnWave's innovative Radiant Energy Vacuum dehydration technology. The exclusive license granted to Bridgford will enable the company to leverage the full potential of REV(TM) technology to produce certain military ration products in the United States of America. Bridgford has also purchased a 120kW REV machine. EnWave's partnership with Bridgford is supported by a manufacturing technology grant, which will guarantee the U.S. Department of Defense certain REV manufacturing capacity at Bridgford's facility to supply close combat field rations. In addition to military ration products, Bridgford will also leverage REV technology to develop additional consumer-branded products at their North Carolina facility. The 120kW REV dehydration machine sold to Bridgford is expected to be commissioned within 2023.

09:08 EDT NextNav announces first European commercial testbed for vertical location tech - NextNav has announced the first European commercial testbed for its high-accuracy Pinnacle vertical location technology. Operating in the Paris area in France, the testbed will demonstrate the benefits Pinnacle can bring to local emergency response agencies and integration with applications and devices from existing NextNav partners. The NextNav testbed near Paris represents the crucial first step in NextNav's vision to offer Europe next-generation 3D GPS services. "We are delighted to introduce a Pinnacle testbed in the Paris area to show how we address the challenge of vertical location accuracy as a first step towards realizing our vision of next-generation GPS services in Europe," said Ambroise Popper, General Manager and Vice President, NextNav France. "This initial deployment will enable us to demonstrate our Pinnacle technology to industry partners and pave the way for delivering not only superior floor-level accuracy, but also resilient 3D PNT capabilities through a terrestrial-based system in the near future."

09:06 EDT Fat Brands announces Fatburger's return to the Tampa, Florida area - FAT announces Fatburger's return to the Tampa area. Located in Riverview, FL, the new restaurant marks the first location in the state in approximately 20 years. The opening is just the start of a new wave of locations arriving in Florida for the all-American burger brand -three more locations will be opening in Tampa in the next five years, in addition to 10 locations in Orlando within the next seven years. "We are heavily invested in growing the Fatburger brand in Florida," said Jake Berchtold, COO of FAT Brands' Fast Casual Division. "Making our return to the state after two decades is incredibly rewarding, especially with a committed, experienced partner like Whole Factor Inc., who will be opening 13 more units in Florida."

09:06 EDT inTEST to be added to Russell 3000 Index & small-cap Russell 2000 on June 26 - inTEST announced it will be added to the Russell 3000 Index, as well as the small-cap Russell 2000 index, effective after the U.S. market opens on June 26. Nick Grant, President and CEO, commented, "We are pleased to be added to the Russell 3000 index as recognition of our growth driven by the effective execution of our Five-Point Strategy. We believe inclusion in the Russell indexes will provide greater exposure to the investment community and increased liquidity in our stock."

09:05 EDT AvePoint adds new functionality for Cloud Backup for Salesforce - AvePoint announced new functionality for Cloud Backup for Salesforce with FedRAMP authorization and the addition of this product to marketplaces - including the AWS Marketplace, Azure Marketplace and Salesforce AppExchange - to provide customers with a flexible acquisition process for their cloud-based products and solutions. Its FedRAMP status is part of AvePoint's commitment to upholding government security standards for government customers, including public sector and federal customers in the United States, and its availability of products across marketplaces demonstrates AvePoint's dedication to streamlining the deployment process.

09:04 EDT Adamas One enters LOI with Neon Flux to manage brand, marketing for Elle Jolie - Adamas One announces it has entered into a Letter of Intent, LOI, with digital agency Neon Flux to oversee its branding, marketing, e-commerce, and fulfillment for Elle Jolie, the Company's luxury jewelry retail business. Adamas One CEO Jay Grdina comments, "Partnering with a well-regarded agency like Neon Flux for our direct-to-consumer initiatives, including managing our e-commerce platform, ElleJoile.com, and the handling of our pick-and-pack fulfillment is an important strategic move that streamlines our marketing, branding, and distribution to a single source that has repeatedly proven to be successful in multiple verticals. We continue to carefully assemble our resources to ensure that our marketing and distribution is as high-quality and forward-thinking as we believe our lab-grown diamond offering to be. We look forward to announcing Neon Flux's progress both in creating our infrastructure and helping to generate revenue."

09:03 EDT Abbott's FreeStyle Libre receives reimbursement in France for basal insulin use - Abbott announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 system to include all people who use basal insulin as part of their diabetes management. FreeStyle Libre 2 was previously covered only for people with Type 1 and Type 2 diabetes who require intensive insulin therapy. The expanded reimbursement enables more people living with diabetes in France1 to access the latest CGM technology. France is the first country in Europe to expand national reimbursement of Abbott's FreeStyle Libre technology to people with diabetes who use basal insulin. This follows similar reimbursement coverage expansions for its technology in Japan and the U.S. Medicare system.

09:02 EDT Virtu Financial launches Alert+ to enhance automated block trading products - Virtu Financial announced the launch of Alert+, a new workflow solution available in POSIT Alert that enhances the features of POSIT Alert by providing automated routing to Virtu's Covert execution algorithm to seek non-displayed liquidity.

08:58 EDT Cenntro gets extension to regain compliance on Nasdaq minimum bid rule - Cenntro Electric Group announced that it received a written notice from The Nasdaq Stock Market granting the Company a 180-day extension, or until December 18, to regain compliance with Nasdaq's $1.00 minimum bid price requirement as set forth in Nasdaq Listing Rule 5550. This Notice has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. On December 22 , Nasdaq notified the Company via notification letter that its ordinary shares had failed to comply with the Rule over the previous 30 consecutive business days. The notification letter stated the Company would be afforded 180 calendar days from the date of the notification letter, or until June 20 to regain compliance with the Rule. The notification letter provided that if the Company did not regain compliance by June 20, the Company may be eligible for an additional 180 calendar day compliance period after June 20.

08:48 EDT Sellas Life Sciences doses first patient in Phase 2a trial of GFH009 - SELLAS Life Sciences announced that the first patient has been dosed in a Phase 2a study of its novel and highly selective CDK9 inhibitor, GFH009, in combination with venetoclax and azacitidine in patients with relapsed/refractory acute myeloid leukemia who did not respond or stopped responding to venetoclax-based therapies. Topline data is expected during the fourth quarter of this year. The Phase 2a clinical trial is an open label, single arm, multi-center study that is designed to evaluate safety, tolerability, and efficacy at two dose levels of GFH009 in combination with aza/ven. The study will enroll up to 20 r/r AML patients, 10 patients per dose level, all of whom will receive standard doses of aza/ven after they became unresponsive to venetoclax combinations including aza/ven, with the addition of GFH009. Treatment will continue for as long as there are no dose limiting toxicities and no progression of disease. Bone marrow will be assessed after the first two infusions of GFH009: at day 14 and day 28. Thereafter, bone marrow assessments will be made every 28 days. In addition to safety and tolerability of GFH009 in combination with aza/ven, the primary endpoints are composite complete response rate and duration of response. Additional endpoints include event free survival, overall survival, and pharmacokinetic and pharmacodynamic assessments.

08:46 EDT Rubicon Technologies enters three-year agreement with Artisent Floors - Rubicon Technologies announced that it has entered into a three-year agreement with Artisent Floors, a flooring solutions provider specializing in multifamily properties.

08:45 EDT FCM says receives 'significant support' from Mind Medicine shareholders at AGM - FCM MM HOLDINGS commented on Mind Medicine's announcement of preliminary results from the 2023 Annual General Meeting of Shareholders and thanks fellow shareholders for their significant show of support at the AGM. The firm said, "FCM has been advised that it won over 50% of the retail shareholder vote, underscoring the widespread concern about MindMed's excessive spending, outrageous executive and director compensation, flawed corporate governance practices, and delayed and mismanaged clinical trials. FCM intends to continue fighting for all shareholders to prevent further value destruction at MindMed. FCM is disappointed that "passive" institutional investors who purport to advocate for "ESG" policies turned a blind eye to serious ethical lapses by current management and saw fit to give incumbent directors another chance...FCM will continue to place pressure on MindMed to live up to their promises to shareholders by: Providing top-line results for the two trials in MM-120 in 2023. Ensuring cash runway into the first half of 2025, without further dilution. Providing substantially enhanced transparency to all shareholders. Detailing its intellectual property strategy in 2023. Ensuring that "one-time" compensation grants to management and the Board are not repeated. FCM will also continue to place pressure on MindMed to act in the interest of its shareholders by: Not substantially diluting shareholders in another destructive financing. Aligning management compensation with shareholder value creation. Fixing MindMed's bylaws to become compliant with NASDAQ listing rules.

08:43 EDT Corebridge reports $200M share repurchase pact with AIG and Blackstone - Corebridge Financial (CRBG) announced that it entered into a share repurchase agreement with American International Group (AIG) and an affiliate of Blackstone (BX) on June 21, pursuant to which it will repurchase an aggregate of $200M of Corebridge common stock. Of the $200M, approximately 90.1% will be repurchased from AIG and approximately 9.9% will be repurchased from Blackstone. The Share Repurchase is expected to close on June 23, subject to customary closing conditions. The purchase price paid by Corebridge was $16.41 per share, the closing price of Corebridge common stock on the New York Stock Exchange immediately prior to entry into the Share Repurchase Agreement

08:39 EDT Verde Bioresins to become public through TLGY Acquisition combination - Verde Bioresins and TLGY Acquisition (TLGY) have entered into a definitive business combination agreement. Upon closing of the business combination, the combined company is expected to list its common stock on Nasdaq under the new ticker symbol (VRDE). The proposed business combination implies an implied pre-money enterprise value for Verde at closing of $365 million (pro forma EV of $433 million), excluding earnouts consideration. The boards of directors of both TLGY and Verde have approved the proposed business combination, which is expected to be completed in the second half of 2023, subject to, among other things, the approval by TLGY's stockholders and satisfaction or waiver of other conditions stated in the definitive documentation. Assuming no further redemptions by TLGY's public stockholders in connection with closing and the payment of estimated transaction expenses, the proposed business combination would result in gross proceeds of over $78M to Verde, comprised of $78M of cash held in TLGY's trust as of the date hereof. Verde's controlling shareholder has committed to making a PIPE investment in TLGY at the closing of the business combination, subject to certain conditions. The proposed business combination includes the entitlement for the equity holders of Verde immediately prior to closing, to receive earnout shares of up to 100% of the closing valuation based on trading prices of the combined company's common stock meeting specified IRR thresholds of 35% over five years. Similarly, TLGY's sponsor has agreed to align its interests with those of Verde and its public shareholders by transferring up to 10% of its private warrants to Verde management and forfeit all of its remaining private warrants at the closing in exchange for potential future share grants based on stock price performance and achieving target cash requirement. TLGY offers a warrant structure that provides an escalating incentive mechanism for its existing public shareholders to not redeem and for new investors to buy common shares before the closing.

08:38 EDT Loop Media expands into Australia and New Zealand with Orange Door partnership - Loop Media and Orange Door, "an established music, video and entertainment distributor in New Zealand," have announced that Loop Media has been added to Orange Door's portfolio of offerings in New Zealand. This partnership allows Orange Door and Loop Media to further expand Orange Door's offerings in New Zealand and Australia and the opportunity to work with all business verticals - including healthcare, office buildings, retail, grocery and c-store sectors - which were previously inaccessible to Orange Door. "Expanding Loop TV into the Australia-New Zealand markets has been on our radar for some time," said Jon Niermann, CEO of Loop Media. "We've had a terrific relationship with Orange Door for years, and this new partnership is the beginning of the opportunity to expand our footprint further into the international market." "By working with Loop Media, we are able to further penetrate into the out-of-home market starting in New Zealand," said Ross Vickers, CEO of Orange Door. "We can now offer additional opportunities and service to the retail, fitness, medical and hospitality sectors with the best-in-class Loop Player and its curated entertainment channels." The partnership kicked off in June 2023.

08:38 EDT Nuo Therapeutics' Aurix System added to WCA formulary - Nuo Therapeutics announces that Wound Care Advantage, WCA, the nation's leading wound care consulting firm has added the Aurix System to its formulary. Wound Care Advantage has established a large network of successful wound healing programs with partner hospitals. Through a strong commitment to quality care and innovation, WCA has built financially sustainable wound care programs that have saved limbs and lives of more than 40,000 patients suffering chronic wounds. "Diabetic foot ulcers pose a significant risk to patients and can be challenging for wound care centers to treat from both clinical and financial perspectives," commented Dave Hazard, Nuo's Vice President of Sales. "With thousands of commercially available wound care products, it can be extremely difficult for wound care centers to identify products that are both reimbursed by Medicare, and more importantly, that actually heal patients. We are excited to partner with Wound Care Advantage's team of experts who rigorously vet each product that is placed on the formulary."

08:37 EDT XR Terra partners with Verizon Innovative Learning HQ - The Glimpse Group announced that its wholly owned subsidiary company XR Terra will be making its XR Foundations for Educators program available on Verizon Innovative Learning HQ, a free education portal available to K-12 educators nationwide.The XR Foundations for Educators program is designed to help teachers gain confidence in the fundamentals of the latest immersive technologies, including AR and VR. The pilot program, which took place during summer and fall 2022, included over 500 teachers from across the U.S. with the goal to expand to an additional 2,000 teachers throughout 2023.

08:36 EDT Society Pass to introduce Society Pass Loyalty App on June 28 - Society Pass will formally introduce its universal loyalty application, Society Pass Loyalty Wallet, at a launch party to be held at Clifford Pier, 80 Collyer Quay, Singapore 049326 at 6 pm on Wednesday, 28 June 2023. In unveiling its paradigm shifting SOPA Loyalty App to +100 invited investors, media, and the general public, SoPa management will showcase the SoPa Loyalty App's ease of use and value proposition for both consumers and merchants to buy, earn and redeem loyalty points, Society Points. In particular, guests will witness SoPa Loyalty App seamless integration with Nusatrip.com, Indonesia's oldest online travel agency, and Gorilla.Global, Society Pass' travel telecoms company. By 4Q 2023, SoPa expects to connect all of its subsidiaries within its ecosystem to the SOPA Loyalty App, enabling an unparalleled shopping experience for its 3.3 million registered consumers and 650,000 registered merchants.

08:35 EDT TeraWulf achieves 5.5 EH/s, 160 MW of bitcoin mining capacity - TeraWulf announced the Company has successfully achieved 5.5 EH/s and 160 MW of operating capacity following the completion of Building 2 at its wholly-owned Lake Mariner facility in New York. TeraWulf can significantly expand mining operations at its existing sites. The Lake Mariner facility can expand by another 100 MW in the near term and up to 500 MW in total. At the nuclear-powered Nautilus facility, TeraWulf retains the option to expand its mining capacity by 50 MW. "Our two sites were strategically developed with expansion potential as a key characteristic. Everything from our power import capacity to the layout of our warehouses and racks is designed to grow," said Paul Prager, Chairman and CEO of TeraWulf. "Scalability and adaptability are vital, and our Lake Mariner and Nautilus facilities possess both. With today's announcement, having achieved 5.5 EH/s and 160 MW of Bitcoin mining capacity as promised, we look forward to now setting our sights on future growth."

08:34 EDT Blue Star Foods pays off $5M asset-based line of credit - Blue Star Foods has paid off its $5M asset based line of credit to a zero balance.

08:33 EDT PaxMedica engages ShareIntel to track market activity - PaxMedica announced that the management and Board of Directors of PaxMedica are aware of the recent market volatility in the company's common stock. PaxMedica is not aware of any news that might be relevant to the recent share price fluctuations, however management takes its fiduciary responsibility very seriously, and have engaged the services of Shareholder Intelligence Services to better understand the investor base and the trading behavior around the company's securities.

08:32 EDT Kymera Therapeutics receives orphan drug designation from U.S. for KT-253 - Kymera Therapeutic announced that the U.S. Food and Drug Administration, FDA, has granted orphan drug designation to KT-253 for the treatment of Acute Myeloid Leukemia, AML. "This orphan drug designation reinforces the potential of KT-253 to advance the treatment of AML by targeting MDM2, a protein that has been challenging to effectively drug with conventional medicines," said Nello Mainolfi, Founder, President and CEO, Kymera Therapeutics. "We have a significant opportunity to deliver an important new medicine that acts on this common cancer mechanism, and we look forward to rapidly advancing KT-253 in AML and exploring its potential in other hematological and solid tumors."

08:22 EDT Better Choice Company trading halted, news pending

08:21 EDT Aeglea BioTherapeutics acquires Spyre Therapeutics - Aeglea BioTherapeutics has completed the acquisition of Spyre Therapeutics, a privately held biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease - IBD -. Concurrent with the acquisition of Spyre, Aeglea entered into a definitive agreement for the sale of Series A non-voting convertible preferred stock in a private placement to a group of institutional accredited investors led by Fairmount Funds Management, with participation from Fidelity Management & Research, Venrock Healthcare Capital, Commodore Capital, Deep Track Capital, Perceptive Advisors, RTW Investments, Cormorant Asset Management, Driehaus Capital, Ecor1 Capital, RA Capital Management, Surveyor Capital and Wellington Management, as well as additional undisclosed institutional investors. The private placement is expected to result in gross proceeds to Aeglea of approximately $210M before deducting placement agent and other offering expenses. The proceeds from the private placement are intended to be used to advance Spyre's portfolio of IBD products through multiple data milestones and are expected to fund operations into 2026. Spyre's lead programs are projected to enter clinical studies in 2024, with clinical data for SPY001 expected by YE2024.

08:19 EDT Mace Security engages Hill View Partners for M&A, capital advisory services - Mace Security International has entered into a consulting engagement with Hill View Partners LLC. Founded in 2016 by Arthur Petropoulos and headquartered in Providence, Rhode Island, Hill View Partners LLC provides Mergers & Acquisitions and Capital Advisory services to companies generating $400,000 to $4,000,000 in EBITDA. The objective of the agreement is to maximize shareholder value by evaluating all options to bridge the gap in its market value and its intrinsic value as well as raise additional capital.

08:18 EDT SOBR Safe, ComplianceOne sign agreement for alcohol testing technology - SOBR Safe has further expanded its sales reach with the signing of alcohol testing distributor ComplianceOne. Kansas-based ComplianceOne was founded in 1987 to provide total management of drug and alcohol testing programs, and now conducts nearly 20,000 tests across 7 states each year. ComplianceOne services approximately 1,100 employers, including numerous prominent consumer and industrial brands. With SOBRsafe, ComplianceOne intends to evolve its customer base beyond reactive measures, instituting preventative alcohol screening as the new standard practice.

08:15 EDT Fintech Ecosystem announces third extension of deadline for combination - Fintech Ecosystem Development announced that its board of directors has decided to extend the date by which the Company must consummate an initial business combination from June 21, 2023 for an additional month, to July 21, 2023, and that its sponsor, Revofast deposited $110,000 into the Company's trust account in connection with this extension, the third of twelve potential one-month extensions of the Deadline Date available to the Company. The Company's Amended and Restated Certificate of Incorporation, as amended, provides the Company with the right to extend the Deadline Date up to twelve times for an additional one month each time, from April 21, 2023 to up to April 21, 2024.

08:13 EDT Versus Systems launches new self-service, AI-powered advertising platform - Versus Systems announced that the Company has now launched a new, self-service version of its powerful digital promotional marketing platform, Winfinite. With the new Winfinite, advertising agencies, brands, and marketers of any size can create their own interactive, rewarded advertising campaigns that drive customer engagement, incremental sales, and consented first-party data collection. "This is a long time coming," said Matthew Pierce, CEO of Versus Systems. "A self-serve version of Versus' Winfinite platform will let any brand create custom, interactive, rewarded games. They will be able to reach new customers and interact with their existing customers in more rewarding ways. With the new AI-powered trivia game coming out of beta next week, our customers will be able to harness the power of machine learning to create simple, fast, and fun interactive experiences in a scalable, low-cost way."

08:11 EDT Verses appoints Darin Bunker as director of engineering - VERSES AI welcomes Darin Bunker as its new Director of Engineering. Bunker will be responsible for accelerating the development of VERSES' network operating system, KOSM, and expanding the adoption of an Agile approach to software development. He joins VERSES from Elementum, where he served as Head of Software Engineering and was instrumental in building a global team of developers utilizing transformational Agile development methodologies which yielded break-through software products to market.

08:10 EDT Inhibikase Therapeutics provides update on leukemia studies - Inhibikase Therapeutics has selected the bioequivalent dose of IkT-001Pro, the company's prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imatinib - marketed as Gleevec - in patients with Chronic Myelogenous Leukemia, or CML, and provided an update on its '501' bioequivalence study. The '501' bioequivalence study has evaluated IkT-001Pro at four single ascending doses of 300, 400, 500 and 600 mg, leading to the selection of 600 mg IkT-001Pro as the bioequivalent dose to 400 mg imatinib mesylate. The company expects to complete the pivotal clinical phase of the study by the end of Q2. Following the completion of the '501' trial, Inhibikase will initiate a discussion with the FDA on the parameters for approval of IkT-001Pro under the 505(b) statute.

08:09 EDT Singing Machine partners with Logistics Plus to manage distribution - The Singing Machine announced it has entered into a logistics agreement with Logistics Plus to distribute Singing Machine's karaoke products throughout the U.S. and Canada. In response to significant rising costs of commercial real estate, labor, and supply-chain costs in southern California, the Company has decided to not renew its lease on its approximate 90,000 sq. ft of warehouse space in Ontario, California. As a result, Singing Machine has opted to shift to a 100% variable-cost model, eliminating unneeded staffing, leasing, warehousing systems and equipment, and other fixed costs. The impact of this shift in operations will allow the Company to eliminate annually in excess of $1.6 million in fixed rent expense and approximately $1.2 million in direct and indirect labor expense. Gary Atkinson, CEO of the Singing Machine said, "With most of our major customers now accepting direct import delivery directly from China, we can pivot away from our need for a fixed in-house logistics solution. This should enable us to be more nimble in response to any changing environment, together with the benefit of working with one solution provider to coordinate all of our distribution throughout North America."

08:08 EDT Seelos Therapeutics closes enrollment in study of SLS-002 - Seelos Therapeutics announced the close of enrollment of its registration directed study of SLS-002 for Acute Suicidal Ideation and Behavior in adults with Major Depressive Disorder. "The close of enrollment of our ASIB study is a major milestone for Seelos and the credit goes to our hard-working clinical team enrolling subjects in this very challenging and difficult-to-treat population. Suicides have devastating effects on families and communities but sadly there is no effective therapy available as of today," said Raj Mehra Ph.D., Chairman and CEO of Seelos. "We look forward to completing the study and sharing the results in the third quarter of 2023."

08:07 EDT Home Depot sets target of 85% battery-powered lawn equipment sales by 2028 - Home Depot expects that by the end of FY28, more than 85% of U.S. and Canada's sales in outdoor power equipment, specifically push lawn mowers and handheld outdoor equipment like leaf blowers and trimmers, will run on rechargeable battery technology instead of gas. This transition will reduce over 2,000,000 metric tons of greenhouse gases annually from exhaust pipes of residential lawn equipment. To reach this goal, The Home Depot will work to extend its position in battery technology and offer cordless outdoor power tools from brands such as Ryobi, Milwaukee, Makita, DeWalt and more.

08:07 EDT Genpact, Coca-Cola HBC partner on digital transformation - Coca-Cola HBC, one of the largest Coca-Cola (KO) strategic bottlers, and Genpact (G) announced a partnership to accelerate digital transformation for CCH's finance operations. Leveraging Genpact's deep domain, process, and digital expertise, the partnership aims to accelerate CCH's transformation by driving process standardization and automation to provide impactful customer experiences and empower CCH to leverage data that turn insights into strategic actions.

08:05 EDT aTyr Pharma announcse EC granted ODD for efzofitimod - aTyr Pharma announced that the European Commission, EC, granted orphan drug designation, ODD, for the company's lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis based on the opinion of the European Medicines Agency, EMA, Committee for Orphan Medicinal Products, COMP. Efzofitimod is currently being investigated in a global pivotal Phase 3 clinical trial in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, and a Phase 2 proof-of-concept study in patients with SSc-ILD is expected to begin in the third quarter of 2023. "We are pleased that the EC recognizes the need for new and impactful treatments for the nearly 100,000 people living with systemic sclerosis in the European Union," said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr. "This orphan drug designation takes into account more than just the rarity of the disease. In addition to the clinical proof-of-concept data generated for efzofitimod in pulmonary sarcoidosis, the COMP considered that the non-clinical in vivo data for efzofitimod in systemic sclerosis, which demonstrated a reduction in the decline of lung function and skin fibrosis not achieved with an authorized medicine in the EU, constitutes a potentially clinically relevant advantage over existing therapies. We believe efzofitimod presents a much-needed opportunity to meaningfully advance treatment options for those whose lungs are affected by systemic sclerosis, and we look forward to the expected initiation of our Phase 2 clinical trial of efzofitimod in patients with SSc-ILD in the third quarter of this year."

08:05 EDT Bowman expands Southwest Gas on-call engagement into Southern Nevada - Bowman Consulting Group (BWMN) announced that the Company has been selected by Southwest Gas Corporation's (SWX) Southern Nevada division for a new multi-year, on-call engineering and land survey services contract. This is in addition to recent extensions of the firm's similar Southern Arizona contracts. Bowman's teams will provide engineering, design and planning, and survey services including right-of-way, property line stakeout, high-pressure line cut sheets and legal exhibits, along with other related services, as required. The Southern Nevada contract is the first Southwest Gas engagement for Bowman in the state. Since 2014, Bowman has delivered survey, civil engineering, design, and planning services to Southwest Gas' Arizona Central and Southern divisions. During that time, Bowman established a relationship built on responsiveness and process improvement that has enabled teaming on hundreds of projects per year and elevated Southwest Gas to one of the Company's largest clients.

08:04 EDT BranchOut Food announces product development program with U.S. Army - BranchOut Food is thrilled to announce its strategic collaboration with the U.S. Army Combat Capabilities Development Command to enhance MREs through the implementation of the BranchOut Food's proprietary GentleDry technology. After comprehensive assessment, DEVCOM has determined that BranchOut's GentleDry technology surpasses freeze-drying methods in several crucial aspects, including nutritional content retention, flavor, and color preservation.

08:03 EDT Kratos Defense expands Space Domain Awareness network locations in India - Kratos Defense & Security Solutions announced an expansion of its Space Domain Awareness network locations into India. Kratos' SDA network monitors the behavior of space-based radio frequency signals to identify critical information about satellites in orbit, such as their position, maneuvering, health, proximity to other satellites and more. It is the world's largest global RF sensor network providing commercially available SDA services in all segments: orbital, link and terrestrial.

08:02 EDT Nexters changes name to GDEV Inc. - Nexters announces that on June 21, 2023, it has changed its name to GDEV Inc. to reflect its evolution as a holding company focused on the growth of its diversified portfolio of studios and franchises. Nexters Global, as a studio, will remain a 100% owned subsidiary of the GDEV holding. Consistent with the name change, GDEV will focus on strategic partnerships, acquisitions and other group-wide initiatives. The holding company will spearhead the expansion of its studios and cross-platform franchises, while each individual studio will concentrate on the development of its own products. The holding company will comprise Nexters, Cubic Games and Dragon Machines, along with partially controlled assets as well as any future acquisitions. The current management team of GDEV will remain unchanged, with each studio operating under its own leadership. The name change will not affect any rights of shareholders, and existing share and warrant certificates will be retained and remain valid. The company's shares and warrants will continue to trade on Nasdaq as "GDEV" and "GDEVW" under the same CUSIPS, G6529J 100 and G6529J 118, respectively, and ISIN numbers, VGG6529J1003 and VGG6529J1185, respectively.

08:02 EDT Bio-Techne to acquire Lunaphore, terms not disclosed - Bio-Techne announced it has reached an agreement to acquire Lunaphore. Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2024. Founded in 2014 and headquartered in Tolochenaz, Switzerland, Lunaphore is a leading developer of fully automated spatial biology solutions using precision microfluidic technology capable of revealing hyperplex proteomic and transcriptomic biomarkers in tumors and other tissues at single-cell and subcellular resolution.

07:59 EDT Harvard Bioscience to join Russell 2000, 3000 Indexes - Harvard Bioscience is set to join the Russell 2000 and Russell 3000 Indexes, according to preliminary membership information posted to the FTSE Russell website. The addition is expected to become effective at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.

07:40 EDT SHF Holdings expands lending, deposit relationship with tier-one MSO - SHF announced that it has expanded its lending and deposit relationship with a tier-one multistate operator, MSO, through the origination of an additional first lien-secured loan in the approximate amount of $2.9 million on a cultivation facility located in a limited license, adult-use cannabis state. "In an environment where other lenders are scaling back, the expansion of Safe Harbor's relationship with this MSO demonstrates the acceleration of our new origination and placement activities and our continued support of the cannabis industry's growth," said Sundie Seefried, Chief Executive Officer at Safe Harbor. "In addition to originating this new loan on a key cultivation property, we are proud to open deposit accounts for this top-performing MSO's operating entities in this key market and to deepen our service relationship."

07:39 EDT PyroGenesis signs two contracts with Aluminerie Alouette for $2.7M - PyroGenesis Canada announces that, further to its Press Releases dated March 17, 2021 and April 20, 2022, the Company has signed two contracts with Aluminerie Alouette for $2.7M. The first contract is to further advance its spent pot lining valorization technology. The second contract is geared to develop a new valorization solution for excess electrolytic bath. Both contracts address primary aluminum production process residue streams. The project funding includes contributions from both Aluminerie Alouette and the Centre quebecois de recherche et de developpement de l'aluminium. The latter administers funding and programs made available by the provincial government's Ministry of the Economy, Innovation and Energy for Quebec's aluminum industry. "We are very proud to be partnering, once again, with Aluminerie Alouette, a company renowned for its environmentally friendly practices and which operates the largest aluminum smelter in the Americas," said Mr. P. Peter Pascali, CEO of PyroGenesis.

07:38 EDT OpGen's subsidiary Curetis receives batch of 10 new C-series Unyvero A30 - OpGen reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats. Andreas Boos, CTO of Curetis and program lead of the Unyvero A30 platform project commented: "We are excited to have taken possession of this newest batch of instruments. With all of the improvements made to date, this is now very close to the final release version of the product. We intend to use the A30 C-Series instruments in all further product development and clinical trials as well as regulatory submissions for our application cartridges on the A30 system." Mr. Boos added that, "all of our ten B-Series instruments have also been upgraded to this latest standard to plan for sufficient A30 instruments to be available for the continued development of our own assays and cartridges in house, and for collaborative projects such as the FIND R&D collaboration which aims to bring an A30 platform and antimicrobial resistance test from blood cultures to low and middle income countries, as well as for other R&D collaboration projects funded by third party partners."

07:37 EDT Adamis participate in White House meeting regarding opioid overdose prevention - Adamis Pharmaceuticals announced that Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals participated in the White House Roundtable with Opioid Reversal Product Manufacturers, hosted by White House Office of National Drug Control Policy Director, Dr. Rahul Gupta, White House Domestic Policy Council Advisor Neera Tanden, U.S. Assistant Secretary for Health Admiral Rachel Levine, and U.S. Assistant Secretary for Mental Health and Substance Use Dr. Miriam E. Delphin-Rittmon. The roundtable discussion was held on June 20, 2023. During the discussion, various members of the Biden/Harris administration passionately discussed the opioid crisis. Dr. Versi added, "This crisis needs to be addressed urgently. Fentanyl and its analogues now cause about 90% of the opioid overdoses, often these are fentanyl poisonings. I believe it is essential to equip first responders with Adamis' ZIMHI injectable naloxone product to deal with this alarming trend. Based on published pharmacokinetic data, ZIMHI results in the most rapid increase in blood levels and achieves the highest blood concentration of naloxone of any of the currently available naloxone products delivered either intranasally or by intramuscular injection."

07:35 EDT Applied Materials to establish collaborative engineering center in India - Applied Materials announced its intention to build a collaborative engineering center in Bangalore, India focused on development and commercialization of technologies for semiconductor manufacturing equipment. The center will be designed to bring together Applied engineers, global and domestic suppliers, and research and academic institutions, enabling them to collaborate in one location with a common goal of accelerating development of semiconductor equipment sub-systems and components. The center will also aim to serve as a catalyst for the training and development of future semiconductor industry talent, as well as open up new opportunities for India to play an expanded role in the global chip ecosystem. "Applied is excited to build upon our 20 years of success in India by creating a facility where the country's top engineers, suppliers and researchers can work side-by-side to develop new innovations," said Prabu Raja, President of the Semiconductor Products Group at Applied Materials. "We envision Applied's strong base of engineering talent collaborating more deeply with domestic and global companies operating in India to strengthen the foundational equipment supply chain serving the global semiconductor manufacturing industry."

07:33 EDT Talaris Therapeutics, Tourmaline Bio to merge in all-stock transaction - Talaris Therapeutics announced that the companies have entered into a definitive agreement under which Tourmaline will combine with Talaris in an all-stock transaction. The combined company will focus on advancing Tourmaline's lead program, TOUR006, a potentially best-in-class anti-IL-6 antibody, for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease. Upon completion of the Merger, the combined company will operate under the name Tourmaline Bio, Inc. and trade on the Nasdaq under the ticker symbol "TRML." In addition, Talaris anticipates making a cash dividend of up to approximately $64.8 million to its stockholders prior to the closing of the Merger. In support of the Merger, Tourmaline has entered into an agreement for a $75 million private placement with a syndicate of new and existing institutional life sciences investors including Acuta Capital Partners, Affinity Asset Advisors, Braidwell LP, Cowen Healthcare Investments, Deep Track Capital, Great Point Partners, LLC, KVP Capital, Logos Capital, Paradigm BioCapital, Qiming Venture Partners USA, RA Capital Management, LP, StemPoint Capital LP, TCGX, Vivo Capital, and other undisclosed investors. Tourmaline previously completed a $112 million Series A financing in 2023 that was co-led by Deep Track Capital, Cowen Healthcare Investments, and TCGX. Tourmaline was founded in September 2021 and initially financed in May 2022 by Hydra, KVP Capital, Petrichor, and QVT Family Office. Tourmaline's lead program, TOUR006, is an anti-IL-6 antibody with best-in-class properties including high binding affinity to IL-6 and a naturally long half-life which potentially enable delivery as a low-volume, infrequently administered, subcutaneous injection. Tourmaline's strategy is to develop TOUR006 in diseases characterized by inflammation and autoantibodies, where IL-6 pathway inhibitors have been underexplored despite compelling signals of clinical benefit. Following this strategy, Tourmaline's lead indication is TED, also known as Graves' ophthalmopathy, an autoimmune disease characterized by inflammation and disfigurement around the eye which can be sight-threatening in severe cases. Off-label use of IL-6 pathway inhibitors in TED has been well-documented in literature demonstrating strong evidence of the ability of such inhibitors to reduce inflammation, eye-bulging, and key biomarkers such as pathogenic autoantibodies. Tourmaline plans to initiate a Phase 2b trial of TOUR006 for the treatment of TED in the third quarter of 2023. The planned second indication for TOUR006 is ASCVD, which continues to be a leading cause of death globally despite the wide availability of oral therapies. IL-6 has been implicated as a promising drug target for addressing ASCVD by over two decades of clinical, genetic, and experimental research. Tourmaline plans to initiate a Phase 2 trial of TOUR006 in ASCVD in 2024. Tourmaline plans to seek additional indication opportunities for TOUR006 among the wide array of diseases where IL-6 inhibition has been validated. TOUR006 was licensed by Tourmaline from Pfizer Inc. in May 2022. Pfizer had completed Phase 1 and Phase 2 trials in other indications with a safety profile consistent with the anti-IL-6 and anti-IL-6R class. Under the terms of the merger agreement, Tourmaline stockholders will receive shares of Talaris common stock upon the consummation of the Merger. In addition to their shares of Talaris common stock, Talaris stockholders will participate in a cash dividend of up to approximately $64.8 million in connection with, and prior to, the Merger. Tourmaline stockholders immediately prior to the Merger are expected to own approximately 78.7% of the combined company and Talaris stockholders immediately prior to the Merger are expected to own approximately 21.3% of the combined company, each on a fully diluted basis. The percentage of the combined company that each company's former stockholders are expected to own may be adjusted based on Talaris' net cash at closing and the proceeds from the sale of certain of Talaris' legacy assets prior to closing. The Merger has been unanimously approved by the Board of Directors of both companies and both Boards of Directors have recommended that their respective stockholders approve the matters regarding the Merger. The Merger is expected to close in the fourth quarter of 2023, subject to approvals by stockholders of each company and other customary closing conditions. In connection with the Merger, directors, officers and certain stockholders of each of Tourmaline and Talaris have executed support agreements, pursuant to the terms of which they have agreed to vote all of their shares of capital stock in favor of the Merger or the issuance of Talaris shares in the Merger, as applicable. Jefferies, Piper Sandler, Guggenheim Securities, and Truist Securities are serving as placement agents to Tourmaline in connection with the private placement and Cooley LLP is serving as legal counsel to Tourmaline in connection with the private placement and the Merger. SVB Securities is serving as exclusive financial advisor to Talaris and Goodwin Procter LLP is serving as legal counsel to Talaris. Following the Merger, the combined company will be led by current members of the Tourmaline leadership team, including: Sandeep Kulkarni, MD, Chief Executive Officer; Yung Chyung, MD, Chief Medical Officer; Brad Middlekauff, JD, Chief Business Officer and General Counsel; Susan Dana Jones, PhD, Chief Technology Officer; Ryan Iarrobino, Senior Vice President, Product Development; Kevin Johnson, PhD, Chief Regulatory Officer; Dora Rau, Senior Vice President, Head of Quality. The merger agreement provides that the Board of Directors of the combined company will be composed of seven board members; five board members, including the CEO of Tourmaline, will be named by Tourmaline and two board members will be named by Talaris.

07:19 EDT Zentek awarded research development contract for ZenARMOR - Zentek has been awarded a research and development contract through Innovative Solutions Canada to test ZenARMOR nano-pigment in military grade, chromate-free, corrosion protection aerospace paint systems. The Company previously announced in its February 8th, 2023, news release that it had been conditionally qualified for the ISC-TS pending a Government of Canada Organization confirming an interest in the ZenARMOR technology. The testing will be conducted under the supervision of Dr. Qi Yang, and Dr. Naiheng Song, Research Officers at the National Research Council of Canada Aerospace Research Centre's Aerospace Manufacturing Technologies Centre. Test Objectives Include: Confirm ZenARMOR meets the required aviation standards; Optimize the concentration of ZenARMOR in aviation paint systems; Compare the corrosion protection of ZenARMOR to chromate-based paint system.

07:13 EDT Tilray's Montauk Brewing launches Peaches & Cream Ale - Montauk Brewing Company shares its latest business updates. The company celebrates their 11-year anniversary with an exclusive launch of their new Peaches & Cream Ale and introduces their new lineup of refreshing craft brews joining its family. Additionally, Montauk brings its Brew Barn to Belmont Park and Saratoga Race Course, kicking off the new summer season. Montauk continues to open new branded spaces in New York, at both Belmont Park and Saratoga Race Course, building off the original Brew Barn name. Belmont Park will feature Montauk's craft beers until July 9, 2023, while at Saratoga Race Course, Montauk Brewing will be showcased in the backyard and Taste NY Pavilion from July 13, 2023, to Labor Day, September 4, 2023.

07:11 EDT OTC Markets Group welcomes Ledyard Financial Group to OTCQX - OTC Markets Group announced Ledyard Financial Group, the holding company for Ledyard National Bank. headquartered in Hanover, New Hampshire, has qualified to trade on the OTCQX Best Market. Ledyard Financial Group, Inc. upgraded to OTCQX from the OTCQB Venture Market.

07:10 EDT PolyPid recruits first patient in revised SHIELD II Phase 3 trial of D-PLEX100 - PolyPid announced that the first patient has been recruited and is scheduled for surgery in its revised SHIELD II Phase 3 trial evaluating D-PLEX100 for the prevention of abdominal colorectal surgical site infections. The U.S. Food and Drug Administration recently accepted the Company's revised protocol for SHIELD II, which is recruiting patients undergoing colorectal resection surgery with large incisions. SHIELD II will enroll an estimated 550 additional patients beyond the 40 patients already recruited into the trial. "The recruitment of the first patient in the revised SHIELD II trial represents a significant milestone for our promising late-stage D-PLEX100 development program and our company," stated Dikla Czaczkes Akselbrad, PolyPid's Chief Executive Officer. "The revised SHIELD II protocol is focused on the population of patients undergoing surgeries with large incisions, which showed a highly statistically significant reduction of 54% in SSIs in SHIELD I. To further de-risk the trial, SHIELD II will primarily be conducted in the best performing sites from SHIELD I as it relates to recruitment, patient monitoring and good clinical practice, and we have enhanced our internal clinical operations capabilities. We are excited to resume the SHIELD II trial and look forward to providing updates on its progress in the coming months."

07:09 EDT GXO, Zalando announce partnership to operate fulfillment center in France - GXO Logistics (GXO) has signed a partnership agreement with Zalando (ZLNDY) for a fulfillment center in Montereau-sur-le-Jard near Paris. The distribution centre will mean that GXO creates approximately 2,000 jobs in the mid-term. "We are delighted to expand our relationship with Zalando with this long-term commitment to manage the company's customer fulfillment in France, in addition to their returns operations in France and Italy," said Rui Marques, Managing Director of France, GXO. "Zalando is our largest project in France to date - in terms of scale, automation, technology and job creation - and we are excited to support Zalando's growth."

07:07 EDT Transcode Therapeutics announces new data relevant to TTX-MC138 - TransCode Therapeutics announced publication of new data relevant to its lead therapeutic candidate, TTX-MC138, in the Journal of Clinical Oncology. The abstract, published in the June 1 supplemental issue of the journal, was presented at the 2023 Annual Meeting of the American Society of Clinical Oncology, ASCO. The study shows that inhibition of microRNA-10b, the therapeutic target of TTX-MC138, in breast cancer cells impaired the capacity of cancer stem cells to create new tumors and become metastatic. TransCode believes that these findings are important because cancer stem cells have long been known to play a critical role in cancer initiation, metastasis, recurrence, and resistance to therapy. TTX-MC138 is designed to inhibit the oncogenic RNA, microRNA-10b, described as the master regulator of cancer progression in a number of advanced solid tumors, including breast cancer. TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers. In a preclinical model of pancreatic adenocarcinoma, administration of TTX-MC138 as monotherapy resulted in complete responses, manifested as regression without recurrence, in 40% of treated animals. This study comes on the heels of preclinical studies in human breast cancer in animals demonstrating complete regressions of metastatic disease. In addition to murine models of cancer, TTX-MC138 was successfully delivered and demonstrated preliminary efficacy in a case study of spontaneous feline mammary carcinoma.

07:07 EDT Praxis Precision Medicines closes financing, reiterates corporate priorities - Praxis Precision Medicines announced the closing of the underwritten public offering of shares of common stock and pre-funded warrants, including the full exercise of the underwriters' overallotment option. The net proceeds from the offering are $63.3 million, after deducting underwriting discounts and commissions and estimated offering expenses. Together with the Company's existing cash, cash equivalents and marketable securities, this extends the cash runway into the first quarter of 2025. The proceeds will be used to advance the development of ulixacaltamide into two Phase 3 studies for essential tremor, to continue clinical development of PRAX-562, PRAX-222 and PRAX-628 for various epilepsies, and for working capital and other general corporate purposes.The Company has initiated a study evaluating PRAX-628 in photo-sensitive epilepsy patients, also known as a PPR study, with expected readout by year end. Similar studies have shown a positive correlation to anti-seizure medicines used to treat focal epilepsy. With this study, Praxis plans to validate the mechanism of action of PRAX-628 and inform the study design for its Phase 2b program. Praxis remains on-track for reading out the Phase 2 Study for PRAX-562 and the first cohort for PRAX-222 in DEEs by year end.

07:05 EDT Invivyd announces initial data from ongoing Phase 1 trial of VYD222 - Invivyd announced positive initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal antibody candidate, VYD222. VYD222 is a broadly neutralizing, half-life extended mAb candidate in development for the prevention of symptomatic COVID-19 in vulnerable populations, such as immunocompromised people. Initial Phase 1 data show that a single administration of VYD222 was generally well-tolerated at all three dose levels tested with no serious adverse events reported to date. At the lowest VYD222 dose tested, geometric mean serum neutralizing titers were 3245.1 against Omicron XBB.1.5 at Day 7, with a geometric mean 38.87-fold rise from baseline to Day 7. Higher VYD222 dose levels tested in the Phase 1 clinical trial are designed to provide greater protection from any potential loss of neutralization activity as SARS-CoV-2 evolves over time. Analysis of the serum neutralizing activity from samples collected at different timepoints across all dose cohorts is ongoing, as is detailed pharmacokinetic analysis and modeling. Invivyd intends to use these analyses, combined with published clinical outcome data from prior clinical trials of vaccines and mAbs for the prevention of symptomatic COVID-19, including data from its Phase 2/3 clinical trial of adintrevimab for the prevention of COVID-19, to inform VYD222 dose selection for its pivotal clinical trial.

07:03 EDT FactSet board approves $300M share repurchase program - FactSet repurchased 165,950 shares of its common stock for $67.1 million at an average price of $404.29 during the third quarter under the Company's existing share repurchase program. As of May 31, 2023, $114.2 million is available for share repurchases under this program. Additionally, on June 20, 2023, the Board of Directors of FactSet approved a new share repurchase authorization of up to $300 million, which will be available on September 1, 2023.

07:01 EDT Darden raises quarterly dividend 8% to $1.31 per share - The dividend is payable on August 1 to shareholders of record at the close of business on July 10.

06:58 EDT Haemonetics receives FDA clearance for NexSys PCS plasma collection system - Haemonetics announced it has received clearance from the FDA for advancements to its NexSys PCS plasma collection system. These include a new plasma collection bowl, featuring a patented design that optimizes performance, and new Express Plus Technology engineered to reduce procedure time.

06:51 EDT ICL lowers 2023 EBITDA view, updates Chinese potash agreement - ICL updated its 2022-2024 framework agreement with its customers in China. The company has agreed to supply those customers with an aggregate amount of 800,000 metric tons of potash during 2023, with mutual options for an additional 350,000 tons. The agreed upon price is $307 per ton, which aligns with recent contract settlements. Due to the lower-than-anticipated potash price, ICL expects to see a negative impact to its 2023 EBITDA guidance of approximately $400M. In addition, a recovery in demand for flame retardants, which was expected in the second half of the year, has not yet begun to materialize. If a recovery is delayed until the end of 2023, it could result in a further reduction of approximately $200M in EBITDA guidance for the year. The company reiterated it is on track with regard to its five-year plan and does not expect these developments to have a material impact on its execution.

06:48 EDT Accenture backs FY23 operating cash flow view $8.7B-$9.2B - For fiscal 2023, the company continues to expect operating cash flow to be in the range of $8.7 billion to $9.2 billion; now expects property and equipment additions to be $600 million, compared to $700 million previously; and now expects free cash flow to be in the range of $8.1 billion to $8.6 billion, compared to $8.0 billion and $8.5 billion previously. The company continues to expect to return at least $7.1 billion in cash to shareholders through dividends and share repurchases.

06:33 EDT Alkermes board election receives ISS recommendation for renewal - Alkermes shareholder Sarissa Capital Management made a statement regarding the recent report on Alkermes issued by independent proxy advisory firm Institutional Shareholder Services, or ISS: "The company has long suffered under the leadership of Chairman and CEO Richard Pops, and the Board has failed to hold him and other members of management accountable, to the significant detriment of the owners of the company-its shareholders......ISS has validated our position and concluded that Sarissa has "made a compelling case that this is the right moment for incremental change in the boardroom." ISS stated in its recent report that: "[T]he persistently negative operating margins, even in the face of the company's commitment to profitability targets, is troubling"; "[T]he implication of this trend [significant increases in SG&A spend relative to sales] is that the company's leadership lacks either the ability or the desire to reduce spending relative to revenue"; "[T]he board's ability to oversee management may be constrained by the combined long tenures of the Chairman/CEO [Richard Pops] (in CEO role since 1991) and [Nancy Wysenski] the lead independent director (10-year board tenure)"; and "[T]he company's leadership has not demonstrated a commitment to lowering costs as a percent of revenues, and there is risk that the spending windfall [from the Janssen settlement] will be squandered..." ISS concluded its analysis by stating that: Sarissa Capital "has made a compelling case that the prolonged inability of the incumbent leadership of Alkermes to transition to profitability warrants change in the boardroom"; and a Sarissa Capital "nominee is needed on the board to add urgency and pressure on management to change".

06:09 EDT MannKind launching Type 1 diabetes study - MannKind is launching the INHALE-3 study to address the most important unmet need today in adults living with Type 1 Diabetes, or T1D. This study is planned to assess improvement in mealtime glycemic control, which continues to be a serious challenge for the majority of people living with type 1 diabetes. INHALE-3 will study the effect of Afrezza on mealtime control. INHALE-3 is a controlled trial with a 13-week extension. The study will randomly assign participants over 18 years of age with T1D who are using MDI, an automated insulin delivery - AID - system, or a pump without automation to either continue their usual care or adopt an insulin regimen of basal injections plus Afrezza. Both arms will utilize continuous glucose monitoring to assess mealtime control and A1c levels.

06:06 EDT Honeywell, Fokker Services sign MOU for repair and overhaul services - Honeywell and Fokker Services have signed a memorandum of agreement whereby Fokker has been authorized as a Service Center & Channel Partner for Honeywell pre-cooler control valve, or PCCV, repair and overhaul services. The agreement, announced at Paris Air Show 2023, will provide airline operators with a wider choice of component repair services. The PCCV is already used on the Boeing 737NG. Through its Amsterdam center, Fokker will offer full disassembly, assembly, test, repair and overhaul services to customers across the globe. This collaboration serves as an expansion of the existing repair authorization for Honeywell avionics and mechanical components, enabling Honeywell and Fokker to venture into new product lines together.

06:04 EDT The Serviceplan Group chooses Box for cloud content management - Box announced that Serviceplan Group selected Box for secure collaboration, enterprise security and compliance. Operating in 16 locations across the globe, with over 5,000 employees, Serviceplan Group is Europe's largest independent and partner-managed agency group. Through Box, Serviceplan Group enables collaboration with internal teams, international subsidiaries, external partners and clients to produce campaigns around advertising, brand awareness and communications.

06:01 EDT Radware announces Signature Partnership with Sycomp - Radware announced Sycomp as a Signature Partner. Joining forces, the companies recently secured a million-dollar deal with one of the top ten biotech companies in the U.S. Sycomp A Technology Company is a global provider of innovative data center, cloud, endpoint, and security services and solutions.

05:25 EDT Triumph Group enters MOU with Stirling Dynamics to collaborate - Triumph Group announced that its Actuation Products & Services business has entered into a memorandum of understanding, or MOU, with Stirling Dynamics outlining their intent to collaborate on advancing opportunities in the electro-mechanical actuation market. The collaboration will include Triumph's extensive design and manufacturing capabilities while utilizing Stirling Dynamics' software and electrical engineering expertise. As operators move towards a more sustainable future, there is an increasing demand for cutting-edge electro-mechanical actuation systems, in both aerospace and defense markets. These systems play a pivotal role in providing precise control of critical aircraft functions such as flight control surfaces and landing gears.

05:15 EDT Clarivate enters strategic partnership with AI21 Labs - Clarivate announced a strategic partnership with AI21 Labs, a pioneer in generative artificial intelligence, or AI. The collaboration will integrate large language models into solutions from Clarivate, to enable intuitive academic conversational search and discovery.

05:10 EDT InterDigital, University of Surrey 6G Innovation Centre enter research pact - InterDigital and the 6G Innovation Centre, or 6GIC, at the University of Surrey have announced a bilateral research partnership to develop 6G enabling technologies that may impact future wireless standards. Specifically, InterDigital will sponsor research and innovation at 6GIC in technologies such as integrated sensing and communication and reconfigurable intelligent surfaces (RIS), both expected to be important features of 6G.